CEREBRAL MALARIA--BIOCHEMICAL PHARMACOLOGY
CEREBRAL MALARIA--BIOCHEMICAL PHARMACOLOGY
批准号:
3747602
负责人:
STEVEN R MESHNICK
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Plasmodium falciparum antimalarial agents antioxidants ascorbate blood chemistry brain disorders chelating agents chelation therapy cooperative study deferoxamine drug interactions drug resistance human therapy evaluation human tissue interferon gamma iron metabolism lipid peroxides malaria mutant nitric oxide oxidative stress serum albumin tocopherols tumor necrosis factor alpha
中文摘要
由多药耐药恶性疟原虫引起的脑型疟疾是一种
严重的公共卫生问题是东南亚。 幸运的是,两个新的
抗疟剂,内过氧化物和铁螯合剂的类别,
对脑型疟疾有效。 这些药物在结构上
与任何喹啉类抗疟药无关,并且没有交叉-
阻力
铁和自由基在铁的作用方式中起着重要的作用。
这两种毒品。 内过氧化物是有效的抗疟药,
内寄生铁催化它们转化为通过去除铁从
一种寄生体内酶 此外,去铁胺的快速效果
可能与其抑制脑脂质代谢有关
过氧化作用 因此,铁和氧化应激都起重要作用,
在两种药物的作用模式中起相反的作用。
该项目代表了拟议的3臂生物化学组件
青蒿琥酯、去铁胺+奎宁和奎宁的临床比较研究
脑型疟疾的治疗。 拟议的研究将有助于
阐明两种药物的作用机制和毒性,并应
帮助选择和发展未来的治疗方案。
1)监测相关生化和寄生虫学参数,
参加临床试验的患者。 我们要找毒品-
在接受青蒿琥酯的患者血清中的烷基化蛋白。 我们
将确定药物如何影响血清氧化应激终点,
铁蛋白 我们还将寻找和鉴定耐药的
突变时复发。
英文摘要
Cerebral malaria due to multidrug-resistant Plasmodium falciparum is a
serious public health problem is Southeast Asia. Fortunately, two new
classes of antimalarial agents, endoperoxides and iron chelator, are
effective in treating cerebral malaria. These drugs are structurally
unrelated to any of the quinoline antimalarial and exhibit no cross-
resistance.
Iron and free radicals play important roles in the modes of action of
both classes of drugs. Endoperoxides are effective antimalarial because
intraparasitic iron catalyzes their conversion into by removing iron from
an intraparasitic enzyme. Furthermore, the rapid effect of deferoxamine
on resolution of coma may be due to its inhibition of cerebral lipid
peroxidation. Thus, both iron and oxidant stress play important albeit
opposite roles in the modes of action of both drugs.
This project represent the biochemical component of the proposed 3-arm
clinical study comparing artesunate, deferoxamine + quinine, and quinine
in the treatment of cerebral malaria. The proposed studies will help
elucidate the modes of action and toxicity of the two drugs, and should
aid in the choice and development of future treatment protocols.
1) Monitor relevant biochemical and parasitological parameters in
patients enrolled in the clinical trials. We will look for drug-
alkylated proteins in the serum of patients receiving artesunate. We
will determine how the drugs affect serum oxidant stress endpoints and
iron proteins. We will also look for and characterized drug-resistant
mutants when recrudescence occur.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BIOCHEMISTRY AND MOLECULAR BIOLOGY OF PNEUMOCYSTIS CARINII
-
批准号:3788892
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEVEN R MESHNICK
-
依托单位:
CEREBRAL MALARIA--BIOCHEMICAL PHARMACOLOGY
-
批准号:3727691
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEVEN R MESHNICK
-
依托单位:
BIOCHEMISTRY AND MOLECULAR BIOLOGY OF PNEUMOCYSTIS CARINII
-
批准号:3766774
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEVEN R MESHNICK
-
依托单位:
BIOCHEMISTRY AND MOLECULAR BIOLOGY OF PNEUMOCYSTIS CARINII
-
批准号:3888185
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEVEN R MESHNICK
-
依托单位:
海外基金